CENTENNIAL, Colo., and RICHMOND, Calif.—The National Stroke Association, a nonprofit that provides stroke education and programs to stroke survivors, caregivers, and the healthcare community, and Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced an educational partnership dedicated to increasing awareness of and access to advance stroke rehabilitation technologies that enable earlier mobility and restored independence for survivors of stroke.
With the joint educational campaign launching today, the National Stroke Association and Ekso Bionics will spearhead strategic initiatives during National Stroke Awareness Month in May and Stroke and Technology Month in November to champion developments in technologies that provide post-stroke independence and improve health outcomes.
Each year, an estimated 17 million people around the world experience a stroke. More than 60% of survivors of acute stroke find themselves unable to walk or in need of intervention in walking. Impaired ambulation is greatly associated with fall risks, dependency, limited participation in social activities, and lower quality of life. However, with the advent of robotic technologies, such as the EksoGT™, the first FDA-cleared exoskeleton device for stroke rehabilitation, the possibility of assisting with ambulation may aid the recovery process by providing earlier mobility and restored independence.
“Thanks to the support of Ekso Bionics, the National Stroke Association will be able to expand the reach of our educational programs and resources for survivors, their care partners and the healthcare community on groundbreaking technologies transforming stroke rehabilitation,” commented Robyn Moore, CEO of the National Stroke Association. “With the increasing use of exoskeletons, such as the EksoGT™ by Ekso Bionics, in stroke rehabilitation, it will be crucial to empower survivors and their circle of care to ensure access and awareness of these advancements throughout North America in the coming years.”
The National Stroke Association’s mission is to reduce the incidence and impact of stroke through education and programs focused on prevention, treatment, rehabilitation and support that addresses the needs of stroke survivors, caregivers and healthcare professionals in the stroke community nationwide. The National Stroke Association provides services to more than 90,000 stroke survivors, 30,000 caregivers and 110,000 healthcare professionals in the U.S and Canada, with the number of individuals benefiting from the National Stroke Association’s services and resources growing every day.
“Ekso Bionics is honored to partner with the National Stroke Association as they share our mission to advance stroke rehabilitation and research,” said Jack Peurach, CEO and President of Ekso Bionics. “The National Stroke Association is a leader in the stroke community that provides a platform for survivors to share their experiences with rehabilitation and recovery, as well as provides information on the latest treatments and technologies. Through this partnership, we will be able to expand awareness and adoption of the EksoGT™, which provides an unparalleled stroke rehabilitation experience and restores hope of early mobility and a return to independence with exoskeleton technology.”
The National Stroke Association and Ekso Bionics educational campaign with include three branches:
- National and Regional Push to Elevate Survivor Voices
- Provide survivors of stroke and their care team with a national and regional platform to share their experiences and showcase the impact of robotic and exoskeleton technologies in providing unparalleled outcomes in rehabilitation.
- Comeback Trail 2018
- As a National Silver Sponsor of the National Stroke Association’s annual Comeback Trail 2018, Ekso Bionics will bolster engagement of local leading stroke rehabilitation centers to ensure survivors have access to the latest advancements in stroke rehabilitation within their reach.
- Sponsored Educational Content
- Publish and promote a series of educational content through Ekso Bionics’ Lean on Me podcast, the National Stroke Association’s monthly e-newsletter, and other platforms to equip survivors of stroke and their care partners with information on the evolving technological landscape in stroke recovery.
About National Stroke Association
The National Stroke Association is the oldest national non-profit in the U.S. that dedicates 100 percent of its efforts on stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke. Visit strokeorg.wpengine.com for more information.
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of a patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps. To date, this device has helped patients take more than 80 million steps in over 185 rehabilitation institutions around the world.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the period and year ended December 31, 2017, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Annual Report on Form 10-K that are required to be included therein, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Jordan Ambron, National Stroke Association